Corcept Therapeutics's revenue for the
three
months ended in Mar. 2026 was €142.6 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was €660.7 Mil.
Corcept Therapeutics's Revenue per Share for the
three
months ended in Mar. 2026 was €1.37.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €5.68.
During the past 12 months, the average Revenue per Share Growth Rate of Corcept Therapeutics was 11.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 22.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 20.00% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 27.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Corcept Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 230.20% per year. The lowest was -57.50% per year. And the median was 30.60% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Corcept Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corcept Therapeutics Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's Revenue distribution charts can be found below:
* The bar in red indicates where Corcept Therapeutics's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €660.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corcept Therapeutics (HAM:HTD) has a Revenue of €660.7 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Corcept Therapeutics and its competitors.
Is Corcept Therapeutics' Revenue too high?
Corcept Therapeutics' current Revenue is €660.7 Mil. Overall, Corcept Therapeutics has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' Revenue compare to PRAX and IBRX?
Corcept Therapeutics' Revenue of €660.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Corcept Therapeutics and its competitors. Corcept Therapeutics's current Revenue is €660.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Corcept Therapeutics (HAM:HTD) has a current Revenue of €660.7 Mil. The stock's GF Value™ is €54.59, compared to a current price of €78.94 — trading 44.6% above its estimated fair value. The current Revenue is €660.7 Mil. Corcept Therapeutics' overall GF Score™ is 85/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Corcept Therapeutics (HAM:HTD), the current Revenue is €660.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corcept Therapeutics (HAM:HTD) Overvalued in 2026?
Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued.
The current stock price of €78.94 is trading 44.6% above its estimated GF Value™ of €54.59.
Key valuation signals for HAM:HTD:
Revenue: €660.7 Mil
GF Value™: €54.59 vs. price of €78.94 (44.6% above fair value)
No single metric tells the full story. See the HAM:HTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
85GF Score
Get the complete analysis for HAM:HTD
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:HTD has been successfully added to your 
